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Abstract
Background: Up to 70% of adolescents with moderate to severe unipolar major depression respond to
psychological treatment plus Fluoxetine (20-50 mg) with symptom reduction and improved social function
reported by 24 weeks after beginning treatment. Around 20% of non responders appear treatment resistant and
30% of responders relapse within 2 years. The specific efficacy of different psychological therapies and the
moderators and mediators that influence risk for relapse are unclear. The cost-effectiveness and safety of
psychological treatments remain poorly evaluated.
Methods/Design: Improving Mood with Psychoanalytic and Cognitive Therapies, the IMPACT Study, will determine
whether Cognitive Behavioural Therapy or Short Term Psychoanalytic Therapy is superior in reducing relapse
compared with Specialist Clinical Care. The study is a multicentre pragmatic effectiveness superiority randomised
clinical trial: Cognitive Behavioural Therapy consists of 20 sessions over 30 weeks, Short Term Psychoanalytic
Psychotherapy 30 sessions over 30 weeks and Specialist Clinical Care 12 sessions over 20 weeks. We will recruit 540
patients with 180 randomised to each arm. Patients will be reassessed at 6, 12, 36, 52 and 86 weeks.
Methodological aspects of the study are systematic recruitment, explicit inclusion criteria, reliability checks of
assessments with control for rater shift, research assessors independent of treatment team and blind to
randomization, analysis by intention to treat, data management using remote data entry, measures of quality
assurance, advanced statistical analysis, manualised treatment protocols, checks of adherence and competence of
therapists and assessment of cost-effectiveness. We will also determine whether time to recovery and/or relapse
are moderated by variations in brain structure and function and selected genetic and hormone biomarkers taken
at entry.
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Background
First depressive episodes tend to arise in vulnerable indi-
viduals exposed to current chronic psychosocial adversi-
ties and acute adverse life events [1-3]. Later episodes of
recurrent disorder are however associated with fewer
external stressors suggesting that a history of depressive
episodes may itself increase the risk of further illness
even in the presence of reduced external adversities
[4,5]. Individuals who experience a depressive episode in
their adolescent years are at higher risk of recurrence
and relapse during their adult life [6]. A history of MD
during adolescence is associated with the subsequent
emergence of personality disorders and substance mis-
use in adult life [7,8]. At least 30% of adult affective dis-
orders start in adolescence and thus reducing the
duration of an episode and the risk for recurrence
would not only reduce short-term morbidity but also
help to prevent depressive conditions and suicidal beha-
viour in later life [9]. Experiencing a depressive episode
at any time during adolescence represents a significant
health and economic burden on the young person, their
family, school and ultimately the gross domestic product
of the nation [10,11]. Additionally, depression in adult
life is amongst one of the top causes of loss of income
to employers in the western world. Therefore, finding
ways to improve treatment and decrease the risk of
recurrent adolescent depression through adequate treat-
ment of early episodes and reducing the risk for relapse
and recurrence would be of a major individual and pub-
lic health advantage. Currently around 1 in 10 cases
referred to CAMHS are identified as having depression
so focusing treatment efforts on this severe group may
have marked clinical and public health benefits through
in adulthood [12].
Treatments for adolescent major depression
One randomised study in the UK showed that even in
adolescent patients who were compliant with full active
treatment for 6 months results were moderate; only 20%
fully recovered, 30% achieved some level of remission, a
further 30% had high number of residual symptoms and
20% did not respond to treatment at all [13]. The possi-
ble reasons for such variable responses to apparently
adequate treatment well delivered and received are
numerous including insufficient treatment dose, higher
non compliance than was measured, incorrect treatment
choice, failure to select out participants with treatment
resistant characteristics and patients who were resistant
to current available therapeutics.
Cognitive Behaviour Therapy (CBT) has been widely
investigated and shown to be effective in the treatment
of mild and moderate depressions in the short term
[9,14]. Recent studies reporting treatment of moderate
to severe depression episodes have shown that the short
term outcomes at 12 weeks for the combination of
Fluoxetine and CBT produces some greater clinical
improvement than CBT alone [15,16]. Depressed adoles-
cents who were treatment resistant at 12 weeks to an
SSRI may show significant clinical improvement with a
change to a different SSRI if prescribed with CBT [17].
A recent meta-analysis of the short term (6-12 weeks)
outcomes from treatment studies suggested adding CBT
to an adequate dose of SSRI provided no statistical
improvement for clinical features but some statistical
benefit for improving social functioning [18]. As yet no
study conducted on depressed adolescents has deter-
mined the effectiveness of any psychological treatment
on the subsequent risk for relapse and recurrence in the
medium term (i.e. 12 -18 months after treatment).
A small study of moderately to severely depressed
young people attending clinical services has shown that
patients may begin to relapse within 3 months of dis-
charge, even in those fully recovered, and over the next
5-10 years some 50%-70% will relapse with a small
group of patients never attaining remission over the
third decade of life [19].
There is now a growing evidence base for psychody-
namic psychotherapy with adults [20,21] including evi-
dence specifically showing the efficacy of treatment for
depressed adults using STPP [22-25]. Relatively few stu-
dies have however tested the effectiveness of psychody-
namic psychotherapy for children and much of the
existing evidence for effectiveness is based on relatively
small scale studies [26]. A chart review study [27] of
763 patients included 65 children and adolescents with
major depression at the Anna Freud Centre who were
treated with long term (average 24 months) psychody-
namic therapy showed that by the end of treatment,
over 75% demonstrated reliable improvement in func-
tioning and no depressive symptoms. A clear dose-
response relationship was also demonstrated with treat-
ment intensity and length of treatment both predicting
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referral. A small pragmatic effectiveness trial of psycho-
dynamic psychotherapy versus family therapy for mild
to moderately depressed children and adolescents aged
9 through to 15 years showed both treatments were as
effective as each other in the short term with a >70%
remission rate for either [28] and two other European
studies have demonstrated the effectiveness of psycho-
dynamic therapy with depressed children and adoles-
cents [29,30].
Specialist Clinical Care (SCC) refers to the active treat-
ment process that is administered routinely in many but
not all UK outpatient child and adolescent mental health
services (CAMHS). Specialist Clinical Care is usually
delivered through a multidisciplinary team and unlike
CBT and STPP is available in the vast majority of all
CAMHS across the UK. This treatment approach has
recently been manualised and is now being taught to
mental health practitioners working in mental health ser-
vices [31]. To date, no studies have investigated the effi-
cacy or effectiveness of SCC alone or against another
psychological treatment. The only UK RCT of adolescent
depression conducted in CAMHS clinics has shown how-
ever that SCC combined with Fluoxetine is as effective as
SCC combined with Fluoxetine and CBT in producing
remission at 28 weeks of treatment [32]. This finding
supports prior research that SCC could be a psychologi-
cal treatment of choice with Fluoxetine if an anti-depres-
sant is required as some cases receiving SCC appear to
enter remission without medication.
Finally interpersonal psychotherapy (IPT), a conversa-
tional treatment with some principles derived from STPP
(e.g. therapeutic relationship development, attending to the
here and now) and SCC (problem solving in the real world
and promoting peer group relationships) has been shown
to be efficacious and effective with children and adolescents
with mild to moderate depression suggesting that relatively
brief, active psychological treatments not focussed on dis-
torted or abnormal cognitive processing treatments are
indeed able to alleviate depressive symptoms and improve
social functioning at least in the short term [33].
In summary there is now substantial data that 3 active
specialist psychological treatments (CBT, STPP, IPT)
derived from different theoretical perspectives and
requiring therapists to be trained in specific modalities
of delivering treatment are efficacious and clinically
effective in alleviating depressive symptoms and improv-
ing social function in the short term in at least 50% of
depressed adolescents. It is likely, but yet to be demon-
s t r a t e dt h a tS C Cw i l lh a v es i m i l a rp r o p e r t i e sf o rt h e
treatment of acute depressive episodes. In contrast there
is no evidence that the successful management of acute
depression in this age range has longer term benefits
through reducing relapse and recurrence risk.
The current randomised controlled trial was designed
firstly to determine i) whether psychological treatment
delivered to moderately to severe depressed adolescents
would reduce risk of relapse and recurrence and if so ii)
which was the most likely to reduce the risk of relapse
12 and 18 months after therapy began. This paper
describes the design of this trial, how we will implement
the protocols and analyse the results.
Methods/Design
Overview
The “Improving Mood with Psychoanalytic and Cogni-
tive Therapies” (IMPACT) study is a pragmatic, relapse
prevention superiority, randomised controlled trial. The
study compares three interventions: Short Term Psycho-
analytic Psychotherapy (STPP), Cognitive Behaviour
Therapy (CBT) and Specialist Clinical Care (SCC) deliv-
ered for the treatment of moderate to severe depression
in adolescents attending routine CAMHS clinics in the
UK. Patients in any arm may receive Fluoxetine 20-50
mg as part of their treatment for reducing clinical symp-
toms and improving social function of the presenting
episode. The use of an SSRI will adhere to UK NICE
guidelines as demonstrated in the ADAPT study [32].
The study will run in three regions: East Anglia, a lar-
gely rural area of 3 million people with 4 cities each
containing approximately 100,00 people each, North
London a densely populated urban sector of the metro-
politan London region with around 4 million people and
the North West of England covering approximately 4
million people of whom about 1 million are living in
rural surroundings with a further 3 million residing in
the northern and central sectors of the large metropoli-
tan area of the City of Manchester. Participants will be
recruited from around 18 routine CAMHS clinics, 6
clinics within each site. The study design will produce
results that will inform which is the most effective treat-
ment in reducing symptoms and improving function in
the short term (12 weeks) and the extended medium
term (i.e. at 36, 52 and 86 weeks) and what is the most
cost-effective treatment. The primary outcome variable
is relapse of depression at 86 weeks measured by adoles-
cent self report and by research assessment of current
mental state. Treatments will be delivered in the usual
clinic settings by staff with training and expertise in one
of each of the three modalities. Therapists will not
cross-over modalities so that they will only deliver the
treatment within which they are qualified.
Aims
To investigate the clinical effectiveness of psychological
treatment in reducing the persistence and/or relapse of
major depression in adolescents. In particular, to determine
whether the specialist individual psychological treatments
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relapse at 86 weeks after treatment had started compared
to SCC. We will test a primary superiority hypothesis that
STPP and CBT are both independently more effective at
reducing relapse risk than SCC and a subsidiary hypothesis
that STPP is more effective than CBT.
To investigate the cost-effectiveness of psychological
treatment and in particular to determine whether the
additional costs of specialised treatment are justified by
improvements in effectiveness and/or decreased use of
health and social care services by 86 weeks follow up.
Eligibility Criteria
Inclusion criteria
Age 11 through 17 years
Current DSM-IV unipolar MDD diagnoses with mod-
erate to severe impairment.
Exclusion criteria
Generalised learning difficulties or a Pervasive Develop-
mental Disorder
Pregnancy
Currently taking another medication that may interact
with an SSRI and unable to stop this medication.
Substance abuse
A primary diagnosis of Bipolar Type I, Schizophrenia
and Eating Disorders
No other exclusions will be made in order to ensure
that the sample is diverse and representative of the kind
of cases that NHS CAMHS take on for treatment.
Recruitment and baseline procedures
The flow of participants from recruitment through to
end of study is shown in figure 1.
The research team will approach local CAMHS within
each of the trial sites and will introduce the study to
staff allowing them to ask questions and become famil-
iar with the objectives of the trial. Identification and
initial screening of potential participants will then be
done by clinical staff working within these clinics, fol-
lowing referral as per usual to specialist CAMHS. In
many cases the clinicians involved in the initial assess-
ments when the potential participants are referred to a
service will be staff who are also delivering treatment as
part of the group, based in clinics. At assessment clini-
cians will be asked to complete a depression screening
tool (see appendix) specifically designed to assist referral
to IMPACT. Once the potential participants are identi-
fied, clinicians will invite the young person and their
carer(s) to take part in the trial. If they are interested
their details will be passed to the research group.
The participants will then be contacted by a
researcher (outcome assessor, OA) who will then sche-
dule an initial meeting during which the participants
will be invited to sign a consent form. All research base-
line assessments will be administered to the young per-
son and their carer in parallel sessions by two research
workers. After this, researchers will confirm whether the
participants meet diagnostic and other entry criteria. If
they do, participants will then be randomised into one
of the treatment arms. Researchers will remain blind to
treatment allocation.
Randomisation procedures and methods to minimise bias
After consent has been obtained and the baseline assess-
ment has been carried out, a trial ID will be assigned. Ran-
domisation will be stratified by age, sex, region and scores
on the Mood and Feelings Questionnaire (MFQ) [34].
Randomisation to treatment arms will be done online by
the trial co-ordinator, thus ensuring allocation conceal-
ment. Information about the treatment allocation will be
forwarded to a clinic administrator who will then be
responsible for allocating a therapist to the participants.
To minimise bias that could arise from knowledge of
treatment allocation the following strategies will be
employed: a) Outcome assessors will be blind to treatment
allocation; b) Outcome assessors and therapist will not
directly (if at all) communicate with each other; c) Out-
come assessors will be asked to guess which treatment
was given so that the effects of possible bias can be exam-
ined in the analysis; and d) all outcome assessor interviews
will be audiotaped and a random sample re-rated by inde-
pendent rates. If blindness is broken, all subsequent
assessments will be carried out by an alternative assessor.
Planned Interventions
IMPACT is a pragmatic superiority trial that seeks to
evaluate the treatments that could be used in standard
   
Screened for 
eligibility (N=) 
Baseline Assessment 
Randomised 
(N=540) 
Excluded 
Not meeting inclusion criteria 
(N=) 
Excluded 
Not meeting inclusion criteria (N=) 
Refused to participate (N=) 
Allocated to SCC 
(N=180) 
Lost to follow-up 
(N=) 
Lost to follow-up 
(N=) 
Lost to follow-up 
(N=) 
Allocated to STPP 
(N=180) 
Allocated to CBT 
(N=180) 
Analysed 
(N=) 
Analysed 
(N=) 
Analysed 
(N=) 
Figure 1 CONSORT flow diagram of progress though the
phases of IMPACT.
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tocols will be used. These are based on usual clinical
practice and have been developed for the trial. The
rational for using treatment protocols is that: a) proto-
cols aid dissemination of treatment methods into clinical
practice; b) they help to standardize the intervention
between therapists and across sites; and c) they form
the bases for audiotape ratings of adherence to the
intervention and thus ensure that the interventions have
been given properly; and importantly d) that therapists
in the SCC group do not give CBT or STPP interven-
tions. The three treatments will be delivered at different
levels of intensity, defined by the total number of ses-
sions over the study period. The number of sessions for
each treatment are as follows: SCC 12 individual ses-
sions plus up to 4 family/marital sessions to be delivered
over 20 weeks, STPP 30 sessions plus 6 parent sessions
to be delivered over 30 weeks and CBT 20 individual
sessions plus up to 4 family/marital sessions to be deliv-
ered over 30 weeks.
Specialist clinical Care (SCC)
SCC will consist of a psychosocial management pro-
gramme with Fluoxetine in severe cases: The procedure
will be a treatment course over 20 weeks maximum con-
sisting first of 6 sessions over the first 8 weeks. If remission
is not achieved psychosocial treatment will be extended
for a further 6 sessions and Fluoxetine added. End of trial
treatment will be denoted by week 20 from the first ses-
sion. The content will involve a conversational approach
with the patient and their parents and siblings if required.
The treatment will emphasise the importance of action-
oriented, goal-focused and interpersonal activities as thera-
peutic strategies. There will be no focus on changing cog-
nitions and negative cognition-driven behaviours will not
be deconstructed. Finally there will be no ongoing analysis
with the patient about the putative unconscious origins of
their symptoms. Advice will b eg i v e no np e r s o n a la c t i v -
ities, social behaviour, and school work and attention will
be paid to immediate distressing events such as family dif-
ficulties. There will be a continuing focus on psycho-edu-
cation, i.e. what depression is/co-morbid diagnoses/how
common it is/its nature and the typical course of the dis-
order/how it affects the adolescent and those around
them. More detailed attention will be paid to the conse-
quences of any acute undesirable life events focused on
the adolescents. Up to 4 family or marital therapy sessions
for parents will be given where required within the 20
week period. Liaison with external agencies and personnel
e.g. teachers, social care and peer group will be underta-
ken. Specific advice will be given on mental and physical
hygiene. Helping oneself through engaging in pleasurable
activities and diminishing solitariness will be strongly
enforced.
SCC will not use cognitive or reflective techniques
related to analysis of unconscious motives and beha-
viours nor specific behavioural strategies. Very ill
patients may require Fluoxetine before 6 sessions have
been delivered. If Fluoxetine is added medical assess-
ment sessions will occur and recorded. The standard
protocol developed for the ADAPT study will be used
whereby a test dose of 10 mg is given for 48 hours fol-
l o w e db y2 0m g .I ft h e r ei sn oi m p r o v e m e n tw i t h i n2 - 4
weeks dose can be adjusted upwards to 60 mg maxi-
mum (median dose in the ADAPT study was 30 mg
with a range of 20 mg-50 mg). Both adverse events and
side effects will be recorded for psychological as well as
pharmacological treatments.
Short Term Psychoanalytic Psychotherapy (STPP)
The form of STPP to be used in the trial, which reflects
the approach to psychodynamic work as it is practiced in
child mental health services in the UK, has been manua-
lised for the study. This manual draws on the work of
other psychodynamic workers [35], including a manual
developed by Marie Rhodes and Judith Trowell (unpub-
lished) at the Tavistock Clinic, where the majority of cur-
rently practicing STPP therapists in the UK have obtained
their training. This treatment manual is specifically aimed
at STPP for young people with depression and was
recently validated in a multisite trial [28]. The IMPACT
manual combines aspects of STPP that focus principally
around techniques aimed at helping young people over-
come developmental problems using both supportive and
expressive strategies by focusing on developmental delays
and distortions in children with severe psychological pro-
blems. The STPP manual outlines the important role for
the interpretation of unconscious conflict, but also makes
extensive use of modern attachment theory and the con-
cepts of internal working models. The intervention aims
to elaborate and increase the coherence of the young per-
son’s maladaptive mental models of attachment relation-
ships and thereby improve their capacity for affect
regulation [36]. The comprehensive implementation of
STPP also involves parallel work with parents or carers
which is also guided by the treatment manual. STPP will
be delivered weekly for 30 weeks. Fluoxetine may be
added in severe cases as per the protocol used in SCC.
Cognitive Behaviour Therapy (CBT)
CBT therapy in this trial is based on that developed for
adults and has been adapted to include parental involve-
ment and specific techniques for adolescents. CBT is an
active, verbal therapy which is based on an individual
formulation of the client’sc u r r e n tp r o b l e m sa n dt h e i r
associated antecedents, precipitating and maintaining
factors. This formulation is shared with the client (and
their parents).
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empiricism’, explicit, tangible and shared goals and clear
structured sessions. Typically therapy has a number of
phases which include assessment, psycho-education into
the cognitive behavioural model of depression (e.g. the
links between thoughts, feelings and behaviours), the
introduction of monitoring methods (e.g. mood, beha-
vioural and thought monitoring), behavioural activation
and activity scheduling, linking thoughts, feelings and
behaviours, identifying and challenging negative auto-
matic thoughts, developing and reinforcing adaptive
thoughts and relapse prevention strategies. Specific tech-
niques have been developed to support therapy and to
maintain engagement and optimism for change. Topics
introduced within therapy session are extended and sup-
ported outside the session by tasks completed by the cli-
e n tb e t w e e ns e s s i o n sa n dr e v i e w e da te a c hs u b s e q u e n t
session. Delivery of the programme is flexible; typically
it may include 12 sessions delivered weekly, followed by
8 biweekly sessions until the end of the treatment. CBT
can be delivered to the adolescent alone or to parents
and the young person together and this is determined
by the formulation.
Assessments and outcome measures
To maximise the clinical validity of the outcome evalua-
tions, these assessments will be made across multiple
domains using multiple methods and sources.
IMPACT Assessment Battery
Interviews
Major depression and co-morbidity - Schedule for
Affective Disorders and Schizophrenia for School Aged
Children (6-18 years) (k-SADS-PL) [37]
Monitoring suicidal adverse events across the treat-
ment trial - Columbia Suicide Severity Rating Scale (C-
SSRS)[38]
Outcomes of child and adolescent psychiatric disor-
ders - The Health of the Nation Outcome Scale for
Children and Adolescents (HoNOSCA)[39]
DSM-IV Borderline personality disorder - Zanarini
Rating Scale for Borderline Personality Disorder (ZAN:
BPD)[40]
Clinical Global Impressions Scale (CGI) [41]
Service use - Child and Adolescent Service Use Sche-
dule (CA-SUS) [42,43]
Self Report
Self-report measure of depressive, anxiety, obsessive-
compulsive and anti-social behaviour symptoms as well
as global self-esteem - The Young Persons questionnaire
(YPQ) containing the Mood and Feelings questionnaire
(MFQ), revised manifest anxiety scale (RCMAS), short
form of the Leyton Obsessional Inventory (LOI), the
Rosenberg self esteem scale (RSES) and an antisocial
behaviour checklist consisting of 11 items derived from
DSM-IV clinical criteria for conduct disorder behaviour
checklist questionnaire [34,44-46]
Responses to low mood - Ruminative Response Scale
[47]
Self–harming and risk-taking behaviour - The Risk
Taking and Self-Harming Inventory for Adolescents
(RTSHIA) [48]
Fundamental emotions - Differential Emotion Scale
(DES-IV)[49]
Experiences associated with depression - Depressive
Experiences Questionnaire (DEQ) [50]
Cognitive vulnerability to depression - Depressed
States Checklist (DSC)[51]
Parenting - Alabama Parenting Questionnaire (APQ)
[52]
Life events - Life Events Questionnaire (LEQ)[1]
Personality - NEO-Five Factor Inventory (NEO-FFI)
[53]
Health-related quality of life - Euroquol (EQ-5D) [54]
Current friendship satisfaction - Friendships Question-
naire [55]
Symptom intensity - Symptom Checklist (SCL:90)[56]
Working Alliance - Working Alliance Inventory -
Short form (WAI-S)[57]
Adolescent Integrative measure (AIM), adaptation of
the HCAM - Hampstead Child and Adaptation Measure
[58]
Family functioning (FAD)[59]
Genetic And Hormone Assays At Entry
At baseline, all participants will be asked to collect saliva
samples at waking, 30 minutes after waking and again at
22.00 hrs for two consecutive days, for cortisol assay.
There is excellent correlation for cortisol levels between
plasma and saliva and also between csf and plasma [60].
Levels will be averaged across the two days to reduce
the effects of day-day variation. This procedure and
assay protocol will be repeated at the 36 week assess-
ment. One further sample of saliva will be collected at
baseline for DNA extraction to test for moderating
effects of gene variants. A first hypothesis will be to
determine the influence of individual differences in sero-
tonergic genes (including triallelic 5-HTTLPR (rs25531)
and 5-HT2A (rs7997012) on treatment response.
We will test whether the 5-HTTLPR s allele, the 5-
HT2A G allele, and high cortisol predict i) time remis-
sion ii) time to relapse iii) differential response to a spe-
cific treatment modality. Naturalistic study has shown
that higher morning cortisol in depressed adolescents is
associated with longer duration of depressive episode
regardless of severity and comorbidity at presentation
[61]. Since higher cortisol impairs memory retrieval for
prior positive events we predict that there will be greater
falls in cortisol in participants that are allocated to
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apy than in those allocated to specialist clinical care.
This is because SCC has a clinical focus on moderating
negative environments and prescribing action strategies
(such as more socialising and peer group meetings)
rather than changing internal cognitions. We will test
whether change in cortisol by 36 weeks will be asso-
ciated with reduced risk of relapse by 86 weeks.
Structure And Function Of Brain Regions Associated With
Emotion And Cognition
There is rapidly emerging evidence for distinctive neural
structural abnormalities associated with affective disor-
ders in young people compared to other psychopatholo-
gies [62]. There is also evidence for neural functions
predicting risk of relapse thati n v o l v ea b n o r m a l i t i e si n
the visual cortical areas as well as the more classical
limbic-frontocortical networks [63]. No studies to date
however have incorporated neuroimaging techniques
within a large RCT of depressed adolescents. In this
trial we will test whether structural and functional dif-
ferences in depressed patients prior to treatment moder-
ate the risk for relapse. We will test whether poor
connectivity between amygdala, anterior cingulate and
medial prefrontal cortex during depression recovers fol-
lowing treatment. We predict that those who continue
to show poor connectivity at 36 weeks after treatment
begins, even if they report less depressive symptoms,
will be at greatest risk of relapse. We will test whether
functional deficits in emotionally valent face perception,
memory, behavioral inhibition and variations in activity
in the visual cortex during these tasks predict risk for
relapse at 36 weeks independently of structural deficits.
To achieve these aims we will recruit 120 participants
(40 from each treatment arm) in the East Anglia Region
to a magnetic resonance imaging study. Of these 40
receiving CBT following randomization will have a sec-
ond scan at 36 weeks. In addition 40 age and sex
matched controls with no lifetime history of depression
will be scanned once only.
Structural MRI datasets (T1-weighted and dual echo
sequences) will be obtained for whole brain, multi-chan-
nel segmentation and voxel based morphometry and
high resolution grey matter volume estimates in limbic
and frontal cortical regions of interest defined a priori
by a parcellated template image. Diffusion tensor ima-
ging (DTI) data will be analyzed for whole brain analysis
of fractional anisotropy measures of white matter inte-
gration and tractography of selected axonal tracts med-
iating connections between limbic and frontal regions of
interest. Twelve diffusion-weighted directed volumes
and 5 volumes without diffusion-weighting (b = 0) will
be acquired. Acquisition time is ~10 minutes.
Functional MRI (fMRI) datasets will be acquired using
Echo-planar images (EPI) depicting BOLD contrast at a
sampling time (TR) of 2 seconds during performance of
three tasks: a facial emotion processing task designed to
activate amygdala and other limbic regions and two
tasks involving executive and mnemonic processing of
emotionally valent stimuli that will additionally activate
prefrontal and medial temporal areas. We will also
acquire fMRI data with participants in a no-task or rest-
ing state to investigate endogenous dynamics and func-
tional connectivity in fronto-limbic circuits. For all fMRI
data acquisitions, but especially for proper control of
potential cardiorespiratory confounds in analysis of rest-
ing state data
52, the respiratory cycle and the inter-beat
interval (RR) in electrocardiographic data will be simul-
taneously recorded in the scanner. Total acquisition
time for all fMRI datasets is ~40 minutes.
Follow-up assessment
Follow-up assessments will be conducted at 6, 12, 36, 52
and 86 weeks after the start of treatment. To monitor
for any adverse events or side effects of therapy, the
researchers will complete the Adverse events/Side effect
questionnaire at each follow-up assessment throughout
the treatment progress [13]. Please refer to Table 1
below for detailed outline of the planned measures for
each follow-up point throughout the trial.
Planned investigations
IMPACT is a pragmatic superiority trial that compares
SCC, CBT and STPP to reduce relapse in adolescents
with DSM-IV defined moderate to severe depression.
Cases with DSM-IV unipolar major depression will be
randomly allocated to SCC, CBT or STPP and outcomes
will be assessed at planned follow-up points by outcome
assessors unaware of the treatment allocation.
Sample size and Power
The proposed design of the trial will run in 6 CAMHS
in each of the three centres, giving 18 clinics with a
minimum of one therapist for each treatment modality
in each clinic. Because IMPACT will involve more than
two treatments, a number of comparisons can be made
between treatment groups. We propose to make two: a)
the two individual specialist treatments CBT and STPP
will be compared; and b) the individual specialist treat-
ments combined will be compared with SCC. A 2.5%
two-tailed significance level has therefore been used in
the power calculation. Additionally, power has been cal-
culated according to each of the following hypothesis of
comparisons: superiority, equivalence or non-inferiority.
It has been assumed that 5 points on the self-report
MFQ is the minimum clinically important difference.
This is approximately 25% of the change in the MFQ
scale from baseline to 28 weeks according to the results
from the ADAPT trial [13] and is equivalent to a 1
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[13]. The ADAPT trial [15] gave an SD for MFQ of 14.6
across follow-up assessments, so that 5 points corre-
sponds to a standardised effect size of about a third
(small to medium) and a non-overlap between treat-
ments of approximately 25% [64]. In the ADAPT trial
the correlation between baseline and follow-up at 28
weeks was approximately 0.5 and the intra-cluster corre-
lation for therapist was less than 0.01 [15]. With 18
therapist in each treatment modality and 10 followed-up
patients per clinic a superiority analysis comparing CBT
and STPP will have a power of over 80% provided that
the intra-cluster correlation for therapists does not
exceed 0.025. By virtue of the increased sample size
comparison of the specialist individual treatments (CBT
and STPP) with SCC will have greater power. These
power calculations assume a cross-sectional analysis, but
statistical analysis will be based on a longitudinal data
using a linear mixed model. The use of such model will
increase the power of the statistical analysis as data is in
effect shared across follow-up time points. ADAPT had
92% follow-up at 28 weeks suggesting a recruited sam-
ple size of approximately 540 patients.
Statistical Analysis Plan
All analysis will be according to intention-to-treat princi-
ple. Characteristics of the treatment groups will be
described at baseline. Preliminary analysis will investigate
the pattern of missing follow-up data. The statistical ana-
lysis of the primary outcome measure (MFQ) and the
secondary measures will estimate the treatment effect
using a linear mixed effects models adjusting for pre-spe-
cified prognostic variables (baseline severity, treatment
centre, co-morbid behavioural and anxiety disorders, sex
and age) and the time point of assessment. The model
will include subject level random intercept and gradient
effects and also random effect for therapist. Ordered
categorical secondary outcome measures such as the CGI
scales and suicidality rating scales will be analysed using
the proportional odds model [65]. A sub-group analysis
by severity will also be conducted using a treatment-
severity interaction term.
Economic evaluation
The objective of the economic evaluation is to evaluate
the relative costs and cost-effectiveness of the three
treatments. Since STPP and CBT are more resource
intensive than best practice SCC, their provision
requires additional health service resources that could
be used elsewhere. To ensure that such resource alloca-
tion is cost-effective, it is necessary to demonstrate that
the additional resources spent can be justified, either in
terms of saving as a result of reduced demand for other
services or in terms of gains in effectiveness.
The economic evaluation will take a societal perspec-
tive, including the use of all health, social care, education
Table 1 Assessments administered at research baseline and each follow-up point throughout the trial
Assessment
points
Interviews Self Report Questionnaires Clinician
Administered
measures
Baseline
(0 weeks)
Adolescent: K-SADS, CGAS, C-SSRS,
ZAN:BPD,HoNOSCA
Carer: K-SADS, CGAS, HoNOSCA, CA-
SUS
Adolescent: YPQ, EQ-5D, RRS, RTSHIA, DSC, DEQ, DES-IV, APQ, LEQ,
FAD & Friendships Questionnaire,
Carer: YPQ, FAD, APQ, LEQ, SCL:90 & Friendships questionnaire
6 weeks Adolescent: K-SADS, CGAS, C-SSRS,
HoNOSCA
Carer: K-SADS, CGAS, HoNOSCA, CA-
SUS
Adolescent: YPQ, EQ-5D, RRS, RTSHIA & WAI-S
Carer: WAI-S & SCL:90
Adolescent: WAI-S & CGI
12 weeks Adolescen:t K-SADS, CGAS, C-SSRS,
HoNOSCA
Carer: K-SADS, CGAS, HoNOSCA, CA-
SUS
Adolescent: YPQ, EQ-5D, RTSHIA, DSC, DES-IV, APQ, LEQ, FAD, WAI-S
& Friendships Questionnaire
Carer: FAD, APQ, LEQ, WAI-S, SCL:90 & Friendships questionnaire
Adolescent: WAI-S & CGI
36 weeks Adolescent: K-SADS, CGAS, C-SSRS,
HoNOSCA
Carer: K-SADS, CGAS, C-SSRS,
HoNOSCA, CA-SUS
Adolescent: YPQ, EQ-5D, RTSHIA & WAI-S
Carer: WAI-S & SCL:90
Adolescent: WAI-S
52 weeks Adolescent: K-SADS, CGAS, C-SSRS,
HoNOSCA, ZAN:BPD
Carer: K-SADS, CGAS, HoNOSCA, CA-
SUS
Adolescent: YPQ, EQ-5D, RTSHIA, RRS, FAD, DSC, DEQ, DES-IV, APQ
& Friendships Questionnaire
Carer: YPQ, FAD, APQ, LEQ, Friendships questionnaire & SCL:90
86 weeks Adolescent: K-SADS, CGAS, C-SSRS,
HoNOSCA
Carer: K-SADS, CGAS, HoNOSCA, CA-
SUS
Adolescent: YPQ, EQ-5D, RTSHIA, RRS & DEQ
Carer: None
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the form of travel to trial intervention sessions and pro-
ductivity losses of the primary carer resulting from their
child’s illness. Economic information will be collected in
interview at baseline and all follow-up points using the
Child and Adolescent Service Use Schedule (CA-SUS),
developed by the applicants in previous research in child
a n da d o l e s c e n tm e n t a lh e a l t h populations and adapted
for the purpose of the current study [42,43]. Data on the
trial interventions, SCC, STPP and CBT will be collected
from clinical records.
The cost of the trial interventions will be calculated
using a bottom-up costing approach [66] which will
involve estimation of indirect time spent on individual
cases, including supervision, as well as detailed recording
of direct face-to-face contacts. Unit costs will be calcu-
lated using data on salaries, employer on-costs (National
Insurance and superannuation), conditions of service and
appropriate administrative, managerial and capital over-
heads [67]. Nationally applicable unit costs will be
applied to all other resources [42,67]. Productivity losses
will be calculated using the human capital approach
which involves multiplying days off work due to illness
by the individual’s salary. The human capital approach
has been criticised for its inability to consider labour
market responses to time off work due to illness and a
tendency to overestimate the true cost of productivity
l o s s e s[ 6 8 ] .T ot a k et h i si n t oa c c o u n t ,t h ei m p a c to fp r o -
ductivity losses will be explored in sensitivity analysis.
Cost-effectiveness will be assessed at the 86 week follow-
up and will be measured in terms of quality adjusted life
years using the EQ-5D measure of health related quality of
life [54]. Cost-effectiveness will initially be explored
through the calculation of incremental cost-effectiveness
ratios (ICER) [69]. Repeat re-sampling (bootstrapping)
from the costs and effectiveness data will then be
employed to generate a distribution of mean costs and
effects for the two treatments [70] which can be used to
calculate the probability that each of the treatments is the
optimal choice subject to a range of possible maximum
values (ceiling ratio) that a decision-maker might be will-
ing to pay for a unit improvement in outcome. Cost-effec-
tiveness acceptability curves will be presented to explore
uncertainty by plotting these probabilities for a range of
possible values of the ceiling ratio [71].
Ethics
The study protocol was approved Cambridgeshire 2
Research Ethics Committee, Addenbrookes Hosptial
Cambridge, UK.
Discussion
The treatment efficacy and effectiveness for unipolar
major depressions in post pubertal adolescents has
established that combination psychological and SSRI
treatment is the therapy of choice for establishing remis-
sion in the short term. Acute treatment appears highly
satisfactory of around 70% of cases regardless of clinical
characteristics. Currently there are very few clinical mar-
kers of poor treatment response to help guide clinicians.
Severity and at presentation suggests a longer time to
recovery but not treatment non response per se [72]. In
contrast non suicidal self injury at presentation is a fre-
quent concomitant of depressive disorders in this age
range and seems non responsive to either CBT or SSRIs
[73]. Thus for those adolescent cases who present with
NSSI there is an increased risk of persistent deleterious
behaviour which itself increases the risk for subsequent
suicidal thoughts and behaviours making it an indirect
risk for depression and perhaps relapse in treatment
response cases [73]. The striking perspective for adoles-
cent mental health services planning is the inability to
denote those depressed young people who are likely to
show persistent depressive illnesses either through non
response and maintenance of a chronic course into
adult life or through a recurrence risk not evident in the
presenting clinical features.
T h ec u r r e n tI M P A C Ts t u d yw a sd e s i g n e dn o to n l yt o
be informative in terms of effective and cost effective
treatment in the short and extended medium term but
uniquely in specifically focusing on reducing relapse risk
in the longer term. A second and important addition is
that one of the treatment arms will for the first time
comprehensively test the effectiveness of a short tem
psychoanalytically psychotherapy, STPP. Comparing the
outcomes of those who received CBT, STPP and SCC
will determine the relative clinical and economic bene-
fits associated SCC and STPP. Furthermore, by collect-
ing regular follow-up data throughout treatment and
then at 52 and 86 weeks, we will be able to explore fac-
tors that might influence treatment response as well as
the long term benefits associated with receiving CBT
and STPP. Treatments will vary in length as stated
within the respective clinical protocols therefore time to
relapse will be calculated from the last treatment session
given. Additionally, the IMPACT trial will give us the
opportunity to examine the productivity losses and
gains of each treatment. This will allow for a set of cal-
culations regarding the treatment costs of each arm and
therefore the overall economic effectiveness of providing
one or more treatments’ to prevent relapse.
IMPACT is also the first study of depression in
young people to include measurement of variables that
can provide insights into the mechanisms that govern
treatment response. Studies of depression in adults
have attempted to establish genetic biomarkers of liabi-
lity for treatment response to SSRIs. A recent meta-
nanlyses of the three published studies to date
Goodyer et al. Trials 2011, 12:175
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Page 9 of 12involving 2998 treated depressed adults in total found
none of the studies reported results that achieved gen-
ome-wide significance, suggesting that larger samples
and better outcome measures will be needed [74].
Indeed the UK GENDEP study has recently suggested
whilst several genetic signals for association with treat-
ment response are worthy of further investigation indi-
vidual gene contributions to depression are likely to
have only minor effects, and very large pooled analyses
will be required to identify them. IMPACT is measur-
ing neural intermediate neural phenotypes as well as
genes and individual differences in cortisol levels. We
will therefore look for main effects of genes on neural
structure and function and cortisol levels and change
between entry and 36 weeks. We will also explore
putative associations between particular clinical pheno-
types including suicidality and NSSI and susceptibility
genes targeted by other studies including GENDEP
and the TORDIA RCT of treatment resistant depressed
adolescents conducted in Pittsburgh, USA [75]. Deter-
mining if there is genetic moderation of intermediate
phenotypes that are associated with treatment response
may be more likely reveal how genetic biomarkers
operate than studies looking for direct associations
with the clinical features.
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